Enliven Therapeutics, Inc.
Lori Anne Kunkel (Director) reports ELVN insider transactions
About this filing
Enliven Therapeutics, Inc. (ELVN) filed Form 4 (insider transaction) with the SEC on Nov 3, 2026. Form 4 reports a company insider’s trades in the company’s shares.
Key facts
- Insider
- Lori Anne Kunkel · Director
| Date | Transaction | Shares | Price | Value | Held after | Ownership |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | M · exercise or conversion of a derivative | +3,741 | $1.12 | $4,189.92 | 45,625 | Direct |
| Oct 30, 2026 | M · exercise or conversion of a derivative | +7,300 | $18.30 | $133,590.00 | 52,925 | Direct |
| Oct 30, 2026 | M · exercise or conversion of a derivativeStock Option (right to buy)Footnotes F1 | −3,741 | $0.00 | $0.00 | 0 | Direct |
| Oct 30, 2026 | M · exercise or conversion of a derivativeStock Option (right to buy)Footnotes F2 | −7,300 | $0.00 | $0.00 | 30,582 | Direct |
Footnotes
- F1 All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- F2 The option, originally for 37,882 shares, of which 7,300 shares have been exercised, vests as to 1/36th of the shares on May 8, 2024 and each month thereafter, subject to the Reporting Person continuing as an outside director through each such date.
More ELVN filings
- 10-Q
Filed Nov 5, 2026
- 8-K
Filed Nov 5, 2026
- SC 13G/A
Filed Oct 27, 2026
- 4
Filed Oct 21, 2026
- 4
Filed Oct 21, 2026
- 144
Filed Oct 19, 2026
Not investment advice. Summaries can contain errors; the SEC filing is the official record.